William H. Chambers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
William H. Chambers has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ian F. Pollack
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
4 shared publications Hideho Okada
University of Pittsburgh Cancer Institute
3 shared publications- Hideho Okada
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
3 shared publications Tianbing Yang
University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213-1863, USA
3 shared publicationsTimothy F. Witham
University of Pittsburgh Cancer Institute
3 shared publicationsDouglas Kondziolka
2 shared publications
Latest Publications
- 1 January 2006
- Published by Springer Nature in Immunologic Research
- Vol. 36 (1-3) , 43-50
CD161B:ClrB Interactions Mediate Activation of Enhanced Lysis of Tumor Target Cells Following NK Cell:DC Co-Culture
Co-culture of natural killer (NK) cells and dendritic cells (DCs) results in their reciprocal co-activation, and an enhancement of lysis of tumor target cells. The receptor:ligand pairings mediating this enhancement are unknown. Therefore, we investigated whether interactions of CD161, on NK cells, with Clrs, on DCs, might have a role in this effect. Blocking expression of CD161B using siRNA resulted in a reduction in enhanced lytic activity following NK:DC co-culture. Conversely, blocking expression of CD161F with siRNA had no effect on enhanced lytic function following NK:DC co-culture. Blocking expression of ClrB/Ocil, a ligand for CD161B, resulted in a reduced level of enhanced lytic function following NK:DC co-culture. This is the first report of NK receptors responsible for interaction with DCs having a role in mediating enhanced lytic function following NK:DC interactions.
- 1 January 2006
- Published by Springer Nature in Immunologic Research
- Vol. 36 (1-3) , 43-50
CD161B:ClrB Interactions Mediate Activation of Enhanced Lysis of Tumor Target Cells Following NK Cell:DC Co-Culture
Co-culture of natural killer (NK) cells and dendritic cells (DCs) results in their reciprocal co-activation, and an enhancement of lysis of tumor target cells. The receptor:ligand pairings mediating this enhancement are unknown. Therefore, we investigated whether interactions of CD161, on NK cells, with Clrs, on DCs, might have a role in this effect. Blocking expression of CD161B using siRNA resulted in a reduction in enhanced lytic activity following NK:DC co-culture. Conversely, blocking expression of CD161F with siRNA had no effect on enhanced lytic function following NK:DC co-culture. Blocking expression of ClrB/Ocil, a ligand for CD161B, resulted in a reduced level of enhanced lytic function following NK:DC co-culture. This is the first report of NK receptors responsible for interaction with DCs having a role in mediating enhanced lytic function following NK:DC interactions.
- 1 August 2003
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 64 (1-2) , 63-69
Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcomain vivo
Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affectedin vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9Lin vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsrin vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.
- 1 August 2003
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 64 (1-2) , 63-69
Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcomain vivo
Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affectedin vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9Lin vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsrin vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.
- 1 September 2002
- Vol. 8 (9) , 2851-5
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Interleukin 13 receptor alpha2-chain (IL-13Ralpha2) has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme. Here we report the identification of a CTL epitope derived from the IL-13Ralpha2. Mature dendritic cells (DCs) were pulsed with each of the synthetic peptides that were designed, based on a binding affinity-based prediction and a proteosomal cleavage site prediction system, and used to stimulate autologous CD8+ T cells from an HLA-A2+ healthy donor. After four to six cycles of restimulation, the immunoreactivity of the T cells was analyzed for specific IFN-gamma production and CTL reactivity. Of the five peptides tested, IL-13Ralpha(345-354) (WLPFGFILI) induced a CD8(+) T-cell line that specifically produced IFN-gamma in response to HLA-A2+ T2 cells pulsed with the relevant peptide and lysed these cells. Peptide titration assays demonstrated that half-maximal lysis of IL-13Ralpha(345-354) peptide-reactive CD8(+) T cells required peptide loading concentration of approximately 5 nM. Perhaps most importantly, this CD8(+) T-cell line also displayed lytic activity against the HLA-A2+ human glioma cell lines that express IL-13Ralpha2. This novel CTL epitope may therefore serve as an attractive component of peptide-based vaccines to treat glioma and as a surrogate marker of T-cell immune responses in patients before and after therapy.
- 1 September 2002
- Vol. 8 (9) , 2851-5
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Interleukin 13 receptor alpha2-chain (IL-13Ralpha2) has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme. Here we report the identification of a CTL epitope derived from the IL-13Ralpha2. Mature dendritic cells (DCs) were pulsed with each of the synthetic peptides that were designed, based on a binding affinity-based prediction and a proteosomal cleavage site prediction system, and used to stimulate autologous CD8+ T cells from an HLA-A2+ healthy donor. After four to six cycles of restimulation, the immunoreactivity of the T cells was analyzed for specific IFN-gamma production and CTL reactivity. Of the five peptides tested, IL-13Ralpha(345-354) (WLPFGFILI) induced a CD8(+) T-cell line that specifically produced IFN-gamma in response to HLA-A2+ T2 cells pulsed with the relevant peptide and lysed these cells. Peptide titration assays demonstrated that half-maximal lysis of IL-13Ralpha(345-354) peptide-reactive CD8(+) T cells required peptide loading concentration of approximately 5 nM. Perhaps most importantly, this CD8(+) T-cell line also displayed lytic activity against the HLA-A2+ human glioma cell lines that express IL-13Ralpha2. This novel CTL epitope may therefore serve as an attractive component of peptide-based vaccines to treat glioma and as a surrogate marker of T-cell immune responses in patients before and after therapy.
- 1 May 2002
- Vol. 62 (9) , 2583-91
Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.
As a means of enhancing immunity to gliomas, we investigated local delivery of rat, bone marrow-derived dendritic cells (DCs) into rat 9L gliosarcoma tumors and into 9L tumors induced to undergo apoptosis by gamma knife radiosurgery. Contrary to other tumors, local delivery of DCs had no therapeutic effect on 9L gliomas, even when tumor apoptosis was induced via radiosurgery, which leads to efficient "loading" of the DCs with tumor antigen. To determine whether antigen-presenting cells, such as DCs, were viable in tumors, we carried out multiparametric staining of 9L tumors, using phycoerythrin-conjugated OX6 (MHC class II) or OX62 (DC specific) and FITC-labeled Val-Ala-Asp-fluoromethyl ketone (FITC-VAD-FMK; activated caspases). It was determined that DCs were undergoing apoptosis in these tumors. We therefore sought to determine which glioma cell surface receptors or components of the extracellular matrix in gliomas influenced DC viability. Hyaluronan (HA) is a major component of glioma extracellular matrix and has been found to support tumor cell migration and metastasis. However, its influence on the immune system, and particularly on DCs, via its receptor CD44 is not well documented. Using reverse transcription-PCR, Northern blot, and Western blot analyses, we determined that HA stimulated production of inducible nitric oxide synthase (iNOS) in DCs. NO production by HA-stimulated DCs was then verified biochemically. NO production was dependent on the size of HA; intermediate HA fragments had the greatest capacity to induce NO production in DC, whereas completely digested HA oligosaccharides failed to induce NO. Furthermore, N-monomethyl-L-arginine, an inhibitor of iNOS, completely blocked HA-induced NO production by DCs. Because induction of NO results in the induction of apoptosis in macrophages as well as other cells, DCs treated with HA were examined for apoptosis in terminal deoxynucleotidyl transferase (TdT)-mediated dUTP biotin nick-end labeling assays. It was demonstrated that HA induced apoptosis in DCs and that induction of apoptosis was dependent on the production of NO because it was entirely inhibited by N-monomethyl-L-arginine. Using flow cytometric analyses with FITC-VAD-FMK, which is specific for activated caspases, we also determined that induction of apoptosis in DCs with HA could be titrated. Coincubation of 9L tumor cells with DCs was found to induce apoptosis in DCs as indicated by fluorescent staining with FITC-VAD-FMK. Specificity of this reaction for CD44-HA interactions was determined by pretreatment of DCs with anti-CD44 or pretreatment of 9L tumor cells with hyaluronidase, which blocked the induction of apoptosis in DCs. These data indicate that HA expressed by gliomas may contribute to their immunosuppressive effects by promoting apoptosis among professional antigen-presenting cells such as DCs via iNOS induction after CD44-HA interactions.
- 1 May 2002
- Vol. 62 (9) , 2583-91
Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.
As a means of enhancing immunity to gliomas, we investigated local delivery of rat, bone marrow-derived dendritic cells (DCs) into rat 9L gliosarcoma tumors and into 9L tumors induced to undergo apoptosis by gamma knife radiosurgery. Contrary to other tumors, local delivery of DCs had no therapeutic effect on 9L gliomas, even when tumor apoptosis was induced via radiosurgery, which leads to efficient "loading" of the DCs with tumor antigen. To determine whether antigen-presenting cells, such as DCs, were viable in tumors, we carried out multiparametric staining of 9L tumors, using phycoerythrin-conjugated OX6 (MHC class II) or OX62 (DC specific) and FITC-labeled Val-Ala-Asp-fluoromethyl ketone (FITC-VAD-FMK; activated caspases). It was determined that DCs were undergoing apoptosis in these tumors. We therefore sought to determine which glioma cell surface receptors or components of the extracellular matrix in gliomas influenced DC viability. Hyaluronan (HA) is a major component of glioma extracellular matrix and has been found to support tumor cell migration and metastasis. However, its influence on the immune system, and particularly on DCs, via its receptor CD44 is not well documented. Using reverse transcription-PCR, Northern blot, and Western blot analyses, we determined that HA stimulated production of inducible nitric oxide synthase (iNOS) in DCs. NO production by HA-stimulated DCs was then verified biochemically. NO production was dependent on the size of HA; intermediate HA fragments had the greatest capacity to induce NO production in DC, whereas completely digested HA oligosaccharides failed to induce NO. Furthermore, N-monomethyl-L-arginine, an inhibitor of iNOS, completely blocked HA-induced NO production by DCs. Because induction of NO results in the induction of apoptosis in macrophages as well as other cells, DCs treated with HA were examined for apoptosis in terminal deoxynucleotidyl transferase (TdT)-mediated dUTP biotin nick-end labeling assays. It was demonstrated that HA induced apoptosis in DCs and that induction of apoptosis was dependent on the production of NO because it was entirely inhibited by N-monomethyl-L-arginine. Using flow cytometric analyses with FITC-VAD-FMK, which is specific for activated caspases, we also determined that induction of apoptosis in DCs with HA could be titrated. Coincubation of 9L tumor cells with DCs was found to induce apoptosis in DCs as indicated by fluorescent staining with FITC-VAD-FMK. Specificity of this reaction for CD44-HA interactions was determined by pretreatment of DCs with anti-CD44 or pretreatment of 9L tumor cells with hyaluronidase, which blocked the induction of apoptosis in DCs. These data indicate that HA expressed by gliomas may contribute to their immunosuppressive effects by promoting apoptosis among professional antigen-presenting cells such as DCs via iNOS induction after CD44-HA interactions.
- 1 August 2001
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 49 (2) , 526
765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results
INTRODUCTION: Patients with recurrent malignant gliomas have a poor prognosis with a median progression-free survival of less than 3 months. The use of novel, immunotherapeutically based strategies represents an appealing approach for such patients, provided issues of safety and efficacy can be confirmed.
- 1 August 2001
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 49 (2) , 526
765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results
INTRODUCTION: Patients with recurrent malignant gliomas have a poor prognosis with a median progression-free survival of less than 3 months. The use of novel, immunotherapeutically based strategies represents an appealing approach for such patients, provided issues of safety and efficacy can be confirmed.
- 1 August 2000
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 47 (2) , 507-508
728 The Characterization of Tumor Apoptosis after Experimental Radiosurgery
Introduction: The biological effects of stereotactic radiosurgery on intracranial tumors are not well characterized, but may involve induction of DNA damage that triggers programmed cell death. We sought to evaluate whether radiosurgery induces apoptosis in an experimental glioma model and to determine whether an increase in apoptotic cell death within glial tumors correlates with improved animal survival.
- 1 August 2000
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 47 (2) , 507-508
728 The Characterization of Tumor Apoptosis after Experimental Radiosurgery
Introduction: The biological effects of stereotactic radiosurgery on intracranial tumors are not well characterized, but may involve induction of DNA damage that triggers programmed cell death. We sought to evaluate whether radiosurgery induces apoptosis in an experimental glioma model and to determine whether an increase in apoptotic cell death within glial tumors correlates with improved animal survival.
- 1 August 2000
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 47 (2) , 506
723 UCN-01 Induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells That Yields a Potent Therapeutic Vaccine Strategy in an Intracranial Glioma Model
Introduction: Our preliminary studies using a syngeneic 9L glioma/Fischer rat model indicate that tumor apoptotic bodies provide a potent source of antigen for delivery to dendritic cells (DCs). In these studies, 7-hydroxystaurosporine (UCN-01), a signal transduction inhibitor, was utilized for induction of glioma cell apoptosis. Subcutaneous vaccination with apoptotic body-pulsed DCs was initiated on the day of intracranial (i.c.) tumor implantation. However, no long-term (>90 days) survivors were observed. We have explored this treatment approach using an intensified vaccination schedule in animals harboring established i.c. tumors as an attempt to affect long term survival.
- 1 August 2000
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 47 (2) , 506
723 UCN-01 Induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells That Yields a Potent Therapeutic Vaccine Strategy in an Intracranial Glioma Model
Introduction: Our preliminary studies using a syngeneic 9L glioma/Fischer rat model indicate that tumor apoptotic bodies provide a potent source of antigen for delivery to dendritic cells (DCs). In these studies, 7-hydroxystaurosporine (UCN-01), a signal transduction inhibitor, was utilized for induction of glioma cell apoptosis. Subcutaneous vaccination with apoptotic body-pulsed DCs was initiated on the day of intracranial (i.c.) tumor implantation. However, no long-term (>90 days) survivors were observed. We have explored this treatment approach using an intensified vaccination schedule in animals harboring established i.c. tumors as an attempt to affect long term survival.